Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michael Damore"'
Autor:
Michael P. Chu, Michael Damore, Noopur Raje, Hoi Kei Lon, Cynthia Basu, Nizar J. Bahlis, Cristina Gasparetto, Michael Sebag, Caitlin Costello, Bhagirathbhai Dholaria, Suzanne Trudel, Harman Dube, Melhem Solh, Andrew Dalovisio, Athanasia Skoura, Moshe Yair Levy, Andrzej Jakubowiak, Michael H. Tomasson, Alexander M. Lesokhin, Edward Chan
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 43, Iss, Pp S195-S196 (2021)
Objectives Elranatamab (PF-06863135) is a humanized bispecific monoclonal antibody (IgG2a) that targets BCMA, a member of the tumor necrosis factor receptor superfamily expressed in multiple myeloma, and CD3 on T cells. We reported results for intrav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::579f0fee7dd908721e3ee7f35b33920c
https://doi.org/10.1016/j.htct.2021.10.331
https://doi.org/10.1016/j.htct.2021.10.331
Autor:
Moshe Yair Levy, Andrzej Jakubowiak, Harman Dube, Melhem Solh, Bhagirathbhai Dholaria, Nizar J. Bahlis, Michael Damore, Michael H. Tomasson, Caitlin Costello, Edward Chan, Alexander M. Lesokhin, Athanasia Skoura, Cristina Gasparetto, Andrew P. Dalovisio, Noopur Raje, Michael Sebag, Hoi Ken Lon, Suzanne Trudel, Michael P. Chu, Cynthia Basu
Publikováno v:
Blood. 138:895-895
Introduction: MagnetisMM-1 (NCT03269136) is a Phase 1 study of elranatamab (PF-06863135), a humanized bispecific molecule that targets BCMA expressed on multiple myeloma (MM) and engages CD3 on T cells, for patients (pts) with relapsed or refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::081d845f232f1ef999afee1dc5a3b2dc
https://doi.org/10.1182/blood-2021-150519
https://doi.org/10.1182/blood-2021-150519
Autor:
Hoi Kei Lon, Bhagirathbhai Dholaria, Suzanne Trudel, Michael Sebag, Michael Damore, Cristina Gasparetto, Andrzej Jakubowiak, Michael H. Tomasson, Nizar J. Bahlis, Edward Chan, Harman Dube, Michael Chu, Andrew P. Dalovisio, Caitlin Costello, Cynthia Basu, Athanasia Skoura, Noopur Raje, Moshe Yair Levy, Alexander M. Lesokhin, Melhem Solh
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S17
Background Elranatamab (PF-06863135), a humanized bispecific molecule, targets both BCMA expressed in MM and CD3 on T cells. MagnetisMM-1 (ClinicalTrials.gov ID: NCT03269136) is a Phase 1 study of elranatamab with the aim of characterizing the effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0c7048def364329190bfc78607ce332e
https://doi.org/10.1016/s2152-2650(21)02100-5
https://doi.org/10.1016/s2152-2650(21)02100-5
Autor:
Moshe Levy, Nizar Bahlis, Noopur Raje, Caitlin Costello, Bhagirathbhai Dholaria, Melhem Solh, Michael Tomasson, Harman Dube, Michael Damore, Hoi Kei Lon, Cynthia Basu, Athanasia Skoura, Edward Chan, Suzanne Trudel, Andrzej Jakubowiak, Michael Chu, Cristina Gasparetto, Andrew Dalovisio, Michael Sebag, Alexander Lesokhin
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S252
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9787ce36a56d2914febc77e078531dad
https://doi.org/10.1016/s2152-2650(21)01578-0
https://doi.org/10.1016/s2152-2650(21)01578-0
Autor:
Bhagirathbhai Dholaria, Michael Chu, Andrew P. Dalovisio, Cynthia Basu, Hoi Kei Lon, Alexander M. Lesokhin, Andrzej Jakubowiak, Suzanne Trudel, Noopur Raje, Moshe Yair Levy, Cristina Gasparetto, Athanasia Skoura, Harman Dube, Michael Sebag, Michael Damore, Melhem Solh, Nizar J. Bahlis, Caitlin Costello, Michael H. Tomasson, Edward Chan
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S439
Context Elranatamab (PF-06863135), a humanized bispecific monoclonal antibody (IgG2a), targets BCMA expressed in MM and CD3 on T-cells. Objective Characterize efficacy, safety, pharmacokinetics, and pharmacodynamics of elranatamab. Design Phase 1 stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d0ee92cd63cc1798cae312ff153c11c
https://doi.org/10.1016/s2152-2650(21)01978-9
https://doi.org/10.1016/s2152-2650(21)01978-9
Autor:
Michael Briskin, Michael Damore, Ronald Law, Grace Lee, Paul W. Kincade, Carol H. Sibley, Michael Kuehl, Randolph Wall
Publikováno v:
Molecular and cellular biology. 10(1)
NF-kappa B activation is a crucial late step in the induction of immunoglobulin kappa light-chain gene expression in pre-B cells by lipopolysaccharide (LPS). We have analyzed NF-kappa B activation in three independent mutant lines of 70Z/3 pre-B cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01464c887c5348f45252f12ac8685398
https://pubmed.ncbi.nlm.nih.gov/2104663
https://pubmed.ncbi.nlm.nih.gov/2104663